Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)
Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)
Shots:
- Under the licensing deal Harbour has global rights of A167 (excl. Greater China), to treat multiple solid and hematological cancers
- Kelun-Biotech will receive an upfront of >$350mn in addition to royalties
- A167 is under clinical Ph I & II in China targeting lymphoma and solid tumors
